Molecular neuropathogenesis of Alzheimers disease: An interaction model stressing the central role of oxidative stress

Future Neurology

Volumn 7, Issue 3, 2012, Pages 287-305

  Rodrigues, Roberto ^a   Smith, Mark A ^b   Wang, Xinglong ^b   Perry, George ^c   Lee, Hyoung Gon ^b   Zhu, Xiongwei ^b   Petersen, Robert B ^b  

^a Case Western Reserve University ^*  (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer's disease; amyloid b; apolipoprotein E; neurofibrillary tangles; Parkinson's disease; reactive oxygen species

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLINE ACETYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRTAZAPINE; SEROTONIN TRANSPORTER; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; APOPTOSIS; COGNITION; DEPRESSION; DISEASE COURSE; ENVIRONMENTAL FACTOR; HEREDITY; HIPPOCAMPUS; HUMAN; LIPID PEROXIDATION; MENTAL STRESS; MOLECULAR BIOLOGY; NEOCORTEX; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPSYCHIATRY; OXIDATIVE STRESS; PANIC; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SENILE PLAQUE;

EID: 84861325995     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.27     Document Type: Review

References (130)

1. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer?s disease. Expert Rev. Neurother. 9(5), 617-630 (2009
2. Beninger RJ, Gerdjikov TV. Dopamine-glutamate interactions in reward-related incentive learning. In: Dopamine and Glutamate in Psychiatric Disorders. Schmidt WJ, Reith EAR (Eds). Humana Press Inc., NJ, USA, 315-350 (2005
3. Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16(13), 4231-4239 (1996
4. Rodrigues R, Bonda DJ, Perry G et al. Oxidative stress and neurodegeneration: an inevitable consequence of aging? Implications for therapy. In: Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner MS (Ed.). Springer Science and Business Media BV, NY, USA, 305-323 (2010
5. Kim JM, Stewart R, Kim SY et al. Synergistic associations of depression and apolipoprotein E genotype with incidence of dementia. Int. J. Geriatr. Psychiatry 26(9), 893-898 (2011
6. Canli T, Omura K, Haas BW, Fallgatter A, Constable RT, Lesch KP. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc. Natl Acad. Sci. USA 102(34), 12224-12229 (2005
7. Smith MA, Rodrigues R. The twin frontiers of depression and Alzheimer?s disease. Front. Neurosci. 3, 236-237 (2009
8. Heininger K. A unifying hypothesis of Alzheimer?s disease. III. Risk factors. Human Psychopharmacol. 15(1), 1-70 (2000
9. Lahiri DK. Apolipoprotein E as a target for developing new therapeutics for Alzheimer?s disease based on studies from protein, RNA, and regulatory region of the gene. J. Mol. Neurosci. 23(3), 225-233 (2004
10. Richey PL, Siedlak SL, Smith MA, Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem. Biophys. Res. Commun. 208(2), 657-663 (1995
11. Deane R, Sagare A, Hamm K et al. ApoE isoform-specific disruption of amyloid b peptide clearance from mouse brain. J. Clin. Invest. 118(12), 4002-4013 (2008
12. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 65(7), 631-641 (2006
13. Cramer PE, Cirrito JR, Wesson DW et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075), 1503-1506 (2012
14. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T. Blocking the apolipoprotein E/ amyloid-beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J. Alzheimers Dis. 24(2), 269-285 (2011
15. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol. Psychiatry 54(7), 665-673 (2003
16. Baum L, Chen L, Ng HK, Pang CP. Apolipoprotein E isoforms in Alzheimer?s disease pathology and etiology. Microsc. Res. Tech. 50(4), 278-281 (2000
17. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer?s disease. Microsc. Res. Tech. 50(4), 305-315 (2000
18. Weisgraber KH, Pitas RE, Mahley RW. Lipoproteins, neurobiology, and Alzheimer?s disease: structure and function of apolipoprotein E. Curr. Opin. Struct. Biol. 4, 507-515 (1994
19. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer?s disease. Lancet 342(8873), 697-699 (1993
20. Bartres-Faz D, Junque C, Moral P, Lopez- Alomar A, Sanchez-Aldeguer J, Clemente IC. Apolipoprotein E gender effects on cognitive performance in age-associated memory impairment. J. Neuropsychiatry Clin. Neurosci. 14(1), 80-83 (2002
21. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71(2), 621S-629S (2000
22. Buttini M, Yu GQ, Shockley K et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22(24), 10539-10548 (2002
23. Fryer JD, Simmons K, Parsadanian M et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25(11), 2803-2810 (2005
24. Desai K, Bruckdorfer KR, Hutton RA, Owen JS. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonistinduced platelet aggregation. J. Lipid Res. 30(6), 831-840 (1989
25. Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 87(13), 5193-5197 (1990
26. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622-630 (1988
27. Hartley DM, Walsh DM, Ye CP et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19(20), 8876-8884 (1999
28. Selkoe DJ. Alzheimer?s disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53(5), 438-447 (1994
29. Rottkamp CA, Raina AK, Zhu X et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 30(4), 447-450 (2001
30. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94(18), 9866-9868 (1997
31. Perry G, Cash AD, Srinivas R, Smith MA. Metals and oxidative homeostasis in Alzheimer?s disease. Drug Dev. Res. 56, 293-299 (2002
32. Wang X, Su B, Siedlak SL et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl Acad. Sci. USA 105(49), 19318-19323 (2008
33. Allaman I, Gavillet M, Belanger M et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J. Neurosci. 30(9), 3326-3338 (2010
34. Combs CK, Karlo JC, Kao SC, Landreth GE. Beta-amyloid stimulation of microglia and monocytes results in TNFalphadependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21(4), 1179-1188 (2001
35. Kienlen-Campard P, Octave JN. Correlation between beta-amyloid peptide production and human APP-induced neuronal death. Peptides 23(7), 1199-1204 (2002
36. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22(12), 4833-4841 (2002
37. Duce JA, Tsatsanis A, Cater MA et al. Iron-export ferroxidase activity of betaamyloid precursor protein is inhibited by zinc in Alzheimer?s disease. Cell 142(6), 857-867 (2010
38. White AR, Bush AI. Metal complexing agents for the treatment of Alzheimer?s disease. Top. Med. Chem. 2, 107-136 (2008
39. Wilhelmus MM, Otte-Holler I, Davis J, Van Nostrand WE, de Waal RM, Verbeek MM. Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J. Neurosci. 25(14), 3621-3627 (2005
40. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer?s disease. Neurobiol. Dis. 9(3), 305-318 (2002
41. Fagan AM, Holtzman DM. Astrocyte lipoproteins, effects of ApoE on neuronal function, and role of ApoE in amyloid-beta deposition in vivo. Microsc. Res. Tech. 50(4), 297-304 (2000
42. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18(1), 195-204 (1998
43. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14(1), 55-61 (1996
44. Shea TB, Rogers E, Ashline D, Ortiz D, Sheu MS. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic. Biol. Med. 33(8), 1115-1120 (2002
45. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci. 23(3), 235-246 (2004
46. Xu F, Simmons B, Reamer RA, Corley E, Murry J, Tschaen D. Chlorination/ cyclodehydration of amino alcohols with SOCl2: an old reaction revisited. J. Org. Chem. 73(1), 312-315 (2008
47. Jablonowska A, Bakun M, Dadlez M. Structural studies of Alzheimer?s disease Abeta peptide oligomers. J. Neurochem. 85 (Suppl. 2), 22 (2003
48. Sadowski MJ, Pankiewicz J, Scholtzova H et al. Blocking the apolipoprotein E/ amyloid-beta interaction as a potential therapeutic approach for Alzheimer?s disease. Proc. Natl Acad. Sci. USA 103(49), 18787-18792 (2006
49. Butterfield DA, GalVan V, Lange MB et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 48(1), 136-144 (2010
50. Koppenol WH. The Haber-Weiss cycle - 70 years later. Redox Rep. 6(4), 229-234 (2001
51. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer?s disease: a central role for bound transition metals. J. Neurochem. 74(1), 270-279 (2000
52. Kontush A, Berndt C, Weber W et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30(1), 119-128 (2001
53. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. A novel action of alzheimer?s amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J. Neurosci. 21(18), 7226-7235 (2001
54. Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA. The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23(7), 1333-1341 (2002
55. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60(8), 759-767 (2001
56. Packer L, Cadenas E. Oxidants and antioxidants revisited. New concepts of oxidative stress. Free Radic. Res. 41(9), 951-952 (2007
57. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer?s disease amyloid beta peptide. Biochim. Biophys. Acta 1768(8), 1976-1990 (2007
58. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol. 65(1), 27-33 (1994
59. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc. Natl Acad. Sci. USA 92(11), 4725-4727 (1995
60. Singh S, Thakur MK. Age-dependent expression of apolipoprotein E in mouse cerebral cortex. J. Mol. Neurosci. 43(3), 251-256 (2010
61. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33(9), 1194-1199 (2002
62. Bullido MJ, Valdivieso F. Apolipoprotein E gene promoter polymorphisms in Alzheimer?s disease. Microsc. Res. Tech. 50(4), 261-267 (2000
63. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178-201 (2008
64. Calabro V, Daugherty MD, Frankel AD. A single intermolecular contact mediates intramolecular stabilization of both RNA and protein. Proc. Natl Acad. Sci. USA 102(19), 6849-6854 (2005
65. Nakamura M, Shishido N, Nunomura A et al. Three histidine residues of amyloidbeta peptide control the redox activity of copper and iron. Biochemistry (Mosc.) 46(44), 12737-12743 (2007
66. Puttfarcken PS, Manelli AM, Falduto MT, Getz GS, LaDu MJ. Effect of apolipoprotein E on neurite outgrowth and beta-amyloidinduced toxicity in developing rat primary hippocampal cultures. J. Neurochem. 68(2), 760-769 (1997
67. Troster AI, Fields JA, Paolo AM, Koller WC. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson?s disease. J. Neurol. Sci. 248(1-2), 62-67 (2006
68. Wolk DA, Dickerson BC. Apolipoprotein E (ApoE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer?s disease. Proc. Natl Acad. Sci. USA 107(22), 10256-10261 (2010
69. Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92(26), 12260-12264 (1995
70. Perry G, Taddeo MA, Petersen RB et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16(1), 77-81 (2003
71. Moreira PI, Nunomura A, Honda K et al. The key role of oxidative stress in Alzheimer?s disease. In: Oxidative Stress and Neurodegenerative Disorders. Qureshi GA, Parvez SH (Eds). Elsevier BV, Amsterdam, The Netherlands, 267-281 (2007
72. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer?s disease. J. Neurosci. 17(8), 2653-2657 (1997
73. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 58(5), 730-735 (2005
74. Perry G, Nunomura A, Raina AK et al. A metabolic basis for Alzheimer disease. Neurochem. Res. 28(10), 1549-1552 (2003
75. Steffens DC, Potter GG, McQuoid DR et al. Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. Am. J. Geriatr. Psychiatry 15(10), 839-849 (2007
76. Cummings JL. The neuropsychiatry of dementing disorders. In: The Neuropsychiatry of Alzheimer?s Disease and Related Dementias, Cummings JL, Vinters HV, Felix J (Eds). Martin Dunitz Ltd, Taylor and Francis Group, London, UK, 1-22 (2003
77. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer?s disease. Biol. Psychiatry 45(4), 422-425 (1999
78. Martinez-Barrondo S, Saiz PA, Morales B et al. Negative evidences in association between apolipoprotein E polymorphism and panic disorder. Eur. Psychiatry 21(1), 59-61 (2006
79. Freeman T, Roca V, Guggenheim F, Kimbrell T, Griffin WS. Neuropsychiatric associations of apolipoprotein E alleles in subjects with combat-related posttraumatic stress disorder. J. Neuropsychiatry Clin. Neurosci. 17(4), 541-543 (2005
80. Caselli RJ, Reiman EM, Hentz JG, Osborne D, Alexander GE. A distinctive interaction between chronic anxiety and problem solving in asymptomatic ApoE e4 homozygotes. J. Neuropsychiatry Clin. Neurosci. 16(3), 320-329 (2004
81. Caselli RJ, Graff-Radford NR, Reiman EM et al. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology 53(1), 201-207 (1999
82. Gallagher-Thompson D, O?Hara R, Simmons A, Kraemer HC, Murphy GM Jr. Apolipoprotein E epsilon4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer?s disease. J. Geriatr. Psychiatry Neurol. 14(3), 115-119 (2001
83. Irie F, Masaki KH, Petrovitch H et al. Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch. Gen. Psychiatry 65(8), 906-912 (2008
84. Casadesus G, Moreira PI, Nunomura A et al. Indices of metabolic dysfunction and oxidative stress. Neurochem. Res. 32(4-5), 717-722 (2007
85. Geda YE, Knopman DS, Mrazek DA et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch. Neurol. 63(3), 435-440 (2006
86. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch. Neurol. 61(8), 1290-1293 (2004
87. Petersen RC, Smith GE, Ivnik RJ et al. Apolipoprotein E status as a predictor of the development of Alzheimer?s disease in memory-impaired individuals. JAMA 273(16), 1274-1278 (1995
88. Sachs-Ericsson N, Joiner T, Plant EA, Blazer DG. The influence of depression on cognitive decline in community-dwelling elderly persons. Am. J. Geriatr. Psychiatry 13(5), 402-408 (2005
89. Wright SL, Persad C. Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates. J. Geriatr. Psychiatry Neurol. 20(4), 189-198 (2007
90. Aboukhatwa M, Dosanjh L, Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer?s disease. Mol. Neurodegener. 5, 10 (2010
91. Le DA, Lipton SA. Potential and current use of N-methyl-d-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 18(10), 717-724 (2001
92. Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47(4), 351-354 (2000
93. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer?s disease: a review. Brain Res. Bull. 61(1), 1-24 (2003
94. Del Prete M, Spaccavento S, Craca A, Fiore P, Angelelli P. Neuropsychiatric symptoms and the ApoE genotype in Alzheimer?s disease. Neurol. Sci. 30(5), 367-373 (2009
95. Han L, McCusker J, Abrahamowicz M, Cole M, Capek R. The temporal relationship between depression symptoms and cognitive functioning in older medical patients - prospective or concurrent? J. Gerontol. A. Biol. Sci. Med. Sci. 61(12), 1319-1323 (2006
96. Han L, McCusker J, Cole M, Abrahamowicz M, Capek R. 12-month cognitive outcomes of major and minor depression in older medical patients. Am. J. Geriatr. Psychiatry 16(9), 742-751 (2008
97. Sun X, Steffens DC, Au R et al. Amyloidassociated depression: a prodromal depression of Alzheimer disease? Arch. Gen. Psychiatry 65(5), 542-550 (2008
98. Emerson JP, Kovaleva EG, Farquhar ER, Lipscomb JD, Que L Jr. Swapping metals in Fe- and Mn-dependent dioxygenases: evidence for oxygen activation without a change in metal redox state. Proc. Natl Acad. Sci. USA 105(21), 7347-7352 (2008
99. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer?s disease pathology. Ann. NY Acad. Sci. 1012, 153-163 (2004
100. Lyketsos CG, Baker L, Warren A et al. Depression, delusions, and hallucinations in Alzheimer?s disease: no relationship to apolipoprotein E genotype. J. Neuropsychiatry Clin. Neurosci. 9(1), 64-67 (1997
101. Hamann S. Cognitive and neural mechanisms of emotional memory. Trends Cogn. Sci. 5(9), 394-400 (2001
102. Czeh B, Michaelis T, Watanabe T et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl Acad. Sci. USA 98(22), 12796-12801 (2001
103. Lupien SJ, de Leon M, de Santi S et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci. 1(1), 69-73 (1998
104. Peavy GM, Lange KL, Salmon DP et al. The effects of prolonged stress and ApoE genotype on memory and cortisol in older adults. Biol. Psychiatry 62(5), 472-478 (2007
105. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 32(7), 1188-1195 (2007
106. Gordon I, Ben-Eliyahu S, Rosenne E, Sehayek E, Michaelson DM. Derangement in stress response of apolipoprotein E-deficient mice. Neurosci. Lett. 206(2-3), 212-214 (1996
107. Fiocco AJ, Poirier J, Joober R, Nair NP, Lupien SJ. Acute and long-term associations between ApoE genetic polymorphism, cortisol levels, and declarative memory performance in older adults. Psychoneuroendocrinology 33(5), 625-633 (2008
108. Felician O, Sandson TA. The neurobiology and pharmacotherapy of Alzheimer?s disease. J. Neuropsychiatry Clin. Neurosci. 11(1), 19-31 (1999
109. Behl C, Lezoualc?h F, Trapp T, Widmann M, Skutella T, Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 138(1), 101-106 (1997
110. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273(5271), 59-63 (1996
111. Vijg J. Aging of the Genome: the Dual Role of the DNA in Life and Death. Oxford University Press, Oxford, UK (2007
112. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 4(9), 529-536 (2003
113. Hamilton ML, Van Remmen H, Drake JA et al. Does oxidative damage to DNA increase with age? Proc. Natl Acad. Sci. USA 98(18), 10469-10474 (2001
114. Perez-Campo R, Lopez-Torres M, Cadenas S, Rojas C, Barja G. The rate of free radical production as a determinant of the rate of aging: evidence from the comparative approach. J. Comp. Physiol. B 168(3), 149-158 (1998
115. Mladenka P, Simunek T, Hubl M, Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic. Res. 40(3), 263-272 (2006
116. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer?s disease. Biochim. Biophys. Acta 1502(1), 139-144 (2000
117. Barja G. Free radicals and aging. Trends Neurosci. 27(10), 595-600 (2004
118. Ritchie K, Kildea D. Is senile dementia ?age-related? or ?ageing-related? - evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 346(8980), 931-934 (1995
119. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci. STKE 2004(225), re5 (2004
120. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70(15), 1258-1264 (2008
121. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem. Res. 32(10), 1749-1756 (2007
122. McEwen BS, Magarinos AM. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Human Psychopharmacol. 16(S1), S7-S19 (2001
123. Rapp MA, Schnaider-Beeri M, Grossman HT et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch. Gen. Psychiatry 63(2), 161-167 (2006
124. Yuan Y, Zhang Z, Bai F et al. Genetic variation in apolipoprotein E alters regional gray matter volumes in remitted late-onset depression. J. Affect. Disord. 121(3), 273-277 (2010
125. Barnes CA. Normal aging: regionally specific changes in hippocampal synaptic transmission. Trends Neurosci. 17(1), 13-18 (1994
126. Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 99(2), 195-231 (1992
127. Rodrigues R. Neuropsychology. A new dimension of the home sapiens. In: [Psychoanalysis and Neuroscience: a Model of the Neurobiology of the Human Personality]. Rodrigues R (Ed.). D.C. Luzzatto Editores, Porto Alegre, Brazil, 215-232 (1985
128. Porter NM, Landfield PW. Stress hormones and brain aging: adding injury to insult? Nat. Neurosci. 1(1), 3-4 (1998
129. Patel JR, Brewer GJ. Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid. J. Neurosci. Res. 86(10), 2303-2313 (2008
130. Mateos AG. Apoptosis in nervous cells. In: Apoptosis: Involvement of Oxidative Stress and Intracellular Ca2+ Homeostasis. Salido GM, Rosado JA (Eds). Springer Science and Business Media B.V., Dordrecht, The Netherlands, 93-128 (2009)